Drug Profile
Raloxifene/Colecalciferol - Alvogen Korea
Alternative Names: DP R213; Raloxifene/CholecalciferolLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Alvogen Korea
- Class Adjuvants; Antineoplastics; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Stilbenes; Vitamin D analogues
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in South Korea
- 29 Mar 2017 Alvogen Korea completes a phase-I trial in Osteoporosis (In volunteers) in South Korea (NCT03010267)